Table 3.

Total-MET-hours and Sex Hormone Levels in EPAT Participants (n=194)

	Beta*	95% Confidence Interval	P-value (Linear trend)	P-value (Quartile Trend)
Placebo participants (n=104)
Estradiol (pg/ml)	−2.84	−8.14, 2.45	0.30	0.91
Estrone (pg/ml)	−9.78	−27.71, 8.14	0.30	0.35
Bioavailable Estradiol (pg/ml)	−3.94	−7.20, −0.69	0.02	0.03
Free Estradiol (pg/ml)	−0.15	−0.28, −0.02	0.02	0.03
Testosterone (ng/dl)	−8.65	−14.94, −2.35	0.007	<0.001
DHEA (ng/ml)	0.11	−0.74, 0.96	0.80	0.80
Androstenedione (pg/ml)	−270.23	−401.22, −139.24	<0.001	<0.001
Bioavailable testosterone (ng/ml)	−6.51	−9.20, −3.83	<0.001	<0.001
Free Testosterone (pg/ml)	−2.99	−4.22, −1.76	<0.001	<0.001
SHBG (nmol/l)	26.52	15.32, 37.71	<0.001	<0.001
Estradiol Participants (n=90)
Estradiol (pg/ml)	−15.56	−36.22, 5.09	0.14	0.04
Estrone (pg/ml)	−44.21	−171.43, 83.01	0.49	0.40
Bioavailable Estradiol (pg/ml)	−8.98	−21.35, 3.39	0.15	0.06
Free Estradiol (pg/ml)	−0.35	−0.84, 0.13	0.15	0.06
Testosterone (ng/dl)	−2.88	−11.47, 5.72	0.51	0.09
DHEA (ng/ml)	−0.11	−0.75, 0.53	0.73	0.86
Androstenedione (pg/ml)	−31.40	−182.11, 119.30	0.68	0.76
Bioavailable testosterone (ng/ml)	0.35	−2.46, 3.16	0.81	0.60
Free Testosterone (pg/ml)	0.14	−1.14, 1.43	0.83	0.59
SHBG (nmol/l)	−11.09	−29.02, 6.83	0.22	0.15

^*Regression coefficient = mean difference in hormone/SHBG level per 100 MET-hours, adjusted for age, race, body mass index, type of menopause

EPAT: Estrogen in the Prevention of Atherosclerosis Trial; MET; Metabolic equivalents of energy expenditure;

SHBG: Sex hormone-binding globulin; DHEA: Dehydroepiandrosterone